WO2023275776A1 - A phytochemical formulation to improve gut health - Google Patents

A phytochemical formulation to improve gut health Download PDF

Info

Publication number
WO2023275776A1
WO2023275776A1 PCT/IB2022/056044 IB2022056044W WO2023275776A1 WO 2023275776 A1 WO2023275776 A1 WO 2023275776A1 IB 2022056044 W IB2022056044 W IB 2022056044W WO 2023275776 A1 WO2023275776 A1 WO 2023275776A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
gut
ferula
asafoeitida
curcuminoids
Prior art date
Application number
PCT/IB2022/056044
Other languages
French (fr)
Inventor
Dr. Sasikumar KUTTAPPAN
Mr. Karthik VARMA
Dr. Augustine AMALRAJ
Original Assignee
Aurea Biolabs Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurea Biolabs Private Limited filed Critical Aurea Biolabs Private Limited
Publication of WO2023275776A1 publication Critical patent/WO2023275776A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger

Definitions

  • the present invention relates to a phytochemical formulation for improvement of gut health. More particularly, the invention relates to a unique phytochemical formulation to maintain a healthy gut micro biota with controlling the inflammatory bowel disease symptoms.
  • gut or gastrointestinal tract is extremely important for overall well-being of the body. Since gut transports food from the mouth to the stomach, converts it into absorbable nutrients and stored energy, and shuttles waste back out of the body, it is also called as second brain of the body. The gut starts from the mouth and end at anus wherein this entire journey of food from mouth and anus determines how healthy a body is. Inflammation anywhere along the digestive tract disrupts this normal process and the main organs food goes through between mouth and anus include esophagus, stomach, small intestine, and large intestine.
  • Gut is full of trillions of bacteria that not only help to process food, but that also help body maintains homeostasis and overall well-being.
  • This microflora may be unique to an individual and is primarily determined by the kind of food, a person consumes and how disciplined life he/she lives in terms of kind of food, sugar/fat levels, exercise, sleep time, medication, and stress levels. Further, research also indicates that babies delivered vaginally grow up to have more diverse microflora than those delivered via C-section, as they get exposed to different bacteria as they pass through the birth canal. Breastfeeding has also been shown to foster beneficial gut bacteria.
  • Gut microflora is key to many aspects of human health including immune system, metabolism and other neuro behavioral traits.
  • the gut microbes are essential for the fermentation of non-digestible substrates like dietary fibers and endogenous intestinal mucus where this fermentation supports the growth of specialist microbes that produce short chain fatty acids (SCFAs) and gases, including acetate, propionate, and butyrate. Therefore, it is important to develop lifestyle habits that lead to good gut health.
  • SCFAs short chain fatty acids
  • IBD inflammatory bowel disease
  • Ulcerative colitis involving inflammation and sores (ulcers) along the superficial lining of your large intestine (colon)
  • rectum and Chron's disease characterized by inflammation of the lining of digestive tract, which often can involve the deeper layers of the digestive tract.
  • IBD generally is considered to be an autoimmune disease, but research suggests that the chronic inflammation may not be due to the immune system attacking the body itself, but it is a result of the immune system attacking a harmless virus, bacteria, or food in the gut, causing inflammation that leads to bowel injury.
  • Inflammatory bowel disease symptoms vary, depending on the severity of inflammation and where it occurs. Symptoms may range from mild to severe. General signs and symptoms that are common to both Crohn's disease and ulcerative colitis include, diarrhea, fatigue, abdominal pain, stomach cramps, blood in your stool, reduced appetite, weight loss and anemia due to blood loss etc.
  • Anti-inflammatory drugs are often the first step in the treatment of inflammatory bowel disease as they decrease inflammation of the digestive tract.
  • the medication generally includes immune suppressants, antidiarrheal drugs and laxatives that affect gut microflora and ecosystem adversely and have several side effects.
  • the control of inflammatory bowel disease directly requires improvement and maintenance of gut health.
  • Various types of medicines are available in the market today that claim to improve gut health. However, they do more harm to the body. There is a need to have a formulation that can naturally build and maintain gut health and reduce chances of developing inflammatory bowel disease.
  • the present invention discloses a formulation for maintaining gut health in humans.
  • the present invention discloses a phytochemical formulation comprising dietary fibers and standardized curcuminoids from Curcuma longa and Ferula asafoeitida extract.
  • the standardized curcuminoids from Curcuma longa and Ferula asafoeitida extract are encapsulated in dietary fibers of turmeric forming a uniform matrix.
  • the phytochemical formulation comprises dietary fibers obtained from Curcuma longa at a concentration of 90% -95%, standardized curcuminoids obtained from Curcuma longa at a concentration of 2% to 5% and Ferula asafoeitida extract at a concentration of 1% to 3%.
  • the formulation of the present invention is a complex of polar and non-polar molecules prepared using the PNS technology. Further, the complex prepared by the PNS technology improves the functional properties of the formulation, stability of the biomolecules, enhance the bio efficacy and controls release of the specific molecule of interest at the targeted tissues.
  • the formulation is prepared in powered form using the spray drying technology to enhance the efficacy of the formulation due to high surface area.
  • Curcuminoids and Ferula asafoeitida extract are encapsulated on the dietary fibers of turmeric to form a firm and uniform complex and the encapsulation is confirmed by various analysis.
  • the formulation is natural, safe, and effective in improving the gut health and in maintaining gut microbiota in humans.
  • FIG 1 tabulates the composition of the phytochemical formulation according to an embodiment of the invention.
  • FIG 2 illustrates the results of UPLC and GC-MS analysis of dietary fibers and the formulation of the present invention.
  • FIG 3 illustrates the results of the (FT-IR) spectra of dietary fibers and the formulation.
  • Gut refers to gastrointestinal tract, which starts from the mouth to the anus which includes all the organs of the digestive system in humans and other animals.
  • IBD Inflammatory Bowel Disease
  • PPS Technology refers to Polar-Nonpolar Sandwich (PNS) Technology, used to increase the bio efficacy of nutraceutieal ingredients.
  • PPS Polar-Nonpolar Sandwich
  • Physical refers to the chemicals produced by plants through primary or secondary metabolism .
  • the present invention relates to a phytochemical formulation to improve the gut health.
  • the formulation comprises the natural ingredients in processed form for maintaining a healthy gut microbiota by controlling the Inflammatory Bowel Disease (IBD) symptoms.
  • IBD Inflammatory Bowel Disease
  • the formulation of the present invention comprises dietary fibers from Curcuma longa, standardized curcuminoids from Curcuma longa and non-volatile Ferula asafoeitida extract formed as a uniform matrix.
  • Curcuma longa commonly termed as turmeric has been traditionally used in various medicines systems across the globe to manage many physical ailments.
  • Asafoetida is the dried latex i.e., gum oleoresin exuded from the rhizome or tap root of several species of Ferula perennial herbs, part of Umbelliferae family.
  • the phytochemical formulation of the present invention has been developed comprising dietary fiber, curcuminoids from Curcuma Longa rhizomes and non-volatile components of Ferula Asafoeitida using Polar-Nonpolar Sandwiching (PNS) Technology.
  • PNS Technology is used to increase the bio-efficacy of nutraceutical ingredients.
  • FIG 1 tabulates the composition of the phytochemical formulation according to an embodiment of the invention.
  • the formulation of the present invention comprises dietary fibers and curcuminoids from Curcuma longa and Ferula asafoeitida extract.
  • the phytochemical formulation comprises dietary fibers obtained from Curcuma longa at a concentration of 90%-95%, standardized curcuminoids obtained from Curcuma longa at a concentration of 2% to 5% and Ferula asafoeitida extract at a concentration of 1% to 3%.
  • the phytochemical formulation is prepared in which the bioactive ingredients curcuminoids and Ferula asafoeitida extract are encapsulated on to the turmeric fiber matrix.
  • the turmeric fiber acts as a suitable carrier for encapsulating the bioactive ingredients to improve the efficacy.
  • the dietary fibers in the formulation influences in the gastrointestinal physiological functions and gut health of the host because of their physiochemical properties and capabilities of fermentation in the gut.
  • the dietary fibers are complex carbohydrates containing of both soluble dietary fibers and insoluble dietary fibers.
  • the soluble dietary fibers are fermented by assuring species of gut bacteria, prominent to physiologically active derivatives whereas the insoluble dietary fibers have significant bulking properties.
  • the dietary fibers are degraded to produce short-chain fatty acids (SCFAs) by intestinal bacteria, which expand gastrointestinal health by stimulating the expression of porcine host defense peptides and altering the gut microbiota.
  • SCFAs short-chain fatty acids
  • the dietary fibers acts as prebiotic by specifically enhancing beneficial gut bacteria and thus improving human healthiness by its physical influence in the gut and improves the gut function.
  • the dietary fibers from Curcuma longa are a modified cell wall component of turmeric and is considered as a suitable carrier to encapsulate bioactive components such as curcuminoids and Ferula asafoeitida extract.
  • bioactive components such as curcuminoids and Ferula asafoeitida extract.
  • the curcuminoids and Ferula asafoeitida extract are encapsulated in the dietary fibers of Curcuma longa.
  • the formulation of the present invention is prepared using the PNS technology in which polar and non-polar molecules are formed as a complex. Further, the complex prepared by the PNS technology improves the functional properties of the formulation, stability of the biomolecules, enhance the bio efficacy and controls release of the specific molecule of interest at the targeted tissues.
  • the formulation is prepared in encapsulated form and is in powder form, which is prepared by spray drying.
  • the powdered form of the encapsulated formulation increases the surface area thus improving the activity of the biomolecules used in the formulation.
  • the mobile phase consists of 40% tetrahydrofuran and 60% water with 1% citric acid.
  • the detection is carried out in an isocratic flow at a wavelength of 420 nm using a photodiode array (PDA) detector.
  • PDA photodiode array
  • the elution is carried out by isocratic method with 1 mL/min flow rate.
  • the volatile oil is hydro-distilled from GHP for 6 h using Clevenger apparatus and dried over anhydrous sodium sulfate and stored in a refrigerator (8 ⁇ 2 °C).
  • the volatile oil is subjected to gas chromatography-mass spectrometry (GC-MS) analysis using Brucker 436-GC, couple with SCION TQMS by Rtx-624 fused silica column with 60 m column length and 0.25 mm internal diameter.
  • GC-MS gas chromatography-mass spectrometry
  • the column temperature is maintained initially at 50 °C and gradually increased to a rate of 10 °C per minute till to attain 230 °C.
  • Helium gas is used as a carrier gas at 1 mL/min of flow rate with constant pressure as 228 kPa.
  • FIG 2 illustrates the results of UPLC and GC-MS analysis of dietary fibers and the formulation of the present invention.
  • the GC-MS analysis of volatile oil of the formulation showed the presence of 2-mercapto-3,4-dimethyl-2,3-dihydrothiophene, n-propyl sec-butyl disulfide, 1 ,2-dithiolane, disulfide bis(l-methylpropyl), 1,3-dithiane, 2,2-bis(methylthio) propane and 1-(1 -propen- l-yl)-2-(2-thiophen-3-yl) disulfide as depicted in FIG 2b.
  • FT-IR Fourier transform infrared
  • FT-IR-460 Fourier transform infrared spectra of dietary fibers and the formulation are recorded by JASCO FT/IR-460 plus instrument in the range of 400-4000 cm -1 with 32 scans per sample using the grounded and blended samples with KBr in a ratio of sample/KBr at 1:4.
  • SEM scanning electron microscopy
  • Elemental analysis is carried out by using Energy-dispersive X-ray spectroscopy (EDS) unit attached with SEM.
  • EDS Energy-dispersive X-ray spectroscopy
  • FIG 3 illustrates the results of the (FT-IR) spectra of dietary fibers and the formulation.
  • the FT-IR spectra of dietary fibers and the formulation are elucidated in FIG. 3a and 3b respectively.
  • the broadened absorption band distinctive to the -OH stretching is observed and attributed to O-H stretching of hydrogen bound to the hydroxyl groups originating mainly from cellulose and hemicelluloses.
  • the bands at 2854 and 2923 cm -1 are due to C-H stretching vibrations, which represented the presence of the typical structure of polysaccharide compounds.
  • the prominent band of C-O-C pyranose ring skeletal vibration stretching around 1020 cm -1 observed in both spectra indicate the presence of xylans and is associated with hemi-celluloses, which confirmed that xyloglucans are strongly bound to dietary fibers and the intense band at this wavenumber proves high cellulose content in the formulation.
  • the peak at 1633 cm -1 corresponded to bending or stretching aromatic hydrocarbons of lignin, which is one more main component of dietary nanofibers.
  • the absorption band at 1155 cm -1 is contributed to the stretching of C-0 groups of C-O-C aliphatic esters.
  • the spectrum exhibited weak to medium intensity bands in the region 626 to 730 cm -1 due to the asymmetric and symmetric C-S stretching vibration due to the presence of more number of sulfur containing compounds which are present in Ferula asafoeitida extract.
  • the characterization of the formulation confirms the encapsulation of curcuminoids and Ferula asafoeitida extract on dietary fibers of Curcuma longa.
  • Example 1 The effect of the formulation in the management of gut health in human.
  • the safety and efficacy of the formulation of the present invention is analyzed for management of gut health and intestinal microflora in humans.
  • a randomized, double- blind, placebo-controlled study is conducted in 30 humans out of which 20 are males and 10 are females, with ages ranging from 22 to 55 years after informed consent and evaluation of inclusion criteria.
  • the effect of the formulation is analyzed on bifidobacteria and lactobacilli that are the indicators for gut health.
  • the formulation of the present invention did not show any significant change in lipid profile such as total cholesterol, triglycerides, HDL-C, LDL-C and VLDL, however, which has a tendency to decrease the levels of total cholesterol as3.90%, HDL-C as -18.37% and VLDL as -1.62%, due to the presence of dietary fibers in the formulation.
  • the placebo group showed increase in total cholesterol as 0.64%, in triglycerides as 43.21% and in VLDL as 43.17%, which are also demonstrated the beneficial effect of the formulation over lipid profile, which is helpful in gastrointestinal and gut related problems and disorders.
  • the formulation of the present invention also exhibited significant reduction in Gastrointestinal Symptom Rating Scale (GSRS) with mean change reduction recorded as -28.57% between the study period, whereas the placebo showed increase in mean changes as 27.27%.
  • GSRS Gastrointestinal Symptom Rating Scale
  • the changes in stool frequency assessed by BSS, the analysis of changes in BSS indicated positive stool changes in treatment group without inducing any adverse effects. This indicates the efficacy of the formulation in improvement of gut health in humans.
  • the formulation of the present invention includes spices, herbs and plant derived phytochemicals having the scientific superiority of low toxicity and superior bio efficacy. As the formulation is derived from the natural ingredients, it is safe for consumption without inducing any adverse effects on gut microflora.
  • the formulation of the present invention prepared by spray drying with improved characteristics such as bulk density is safe and effective in improvement of gut health micro biota by controlling the inflammatory bowel disease symptoms.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to a phytochemical formulation for maintaining a healthy gut micro biota with controlling the inflammatory bowel disease symptoms. The phytochemical formulation comprises dietary fibers obtained from Curcuma longa at a concentration of 90%-95%, standardized curcuminoids obtained from Curcuma longa at a concentration of 2% to 5% and Ferula asafoeitida extract at a concentration of 1% to 3%. Curcuminoids and Ferula asafoeitida extract are encapsulated onto the dietary fibers to form a complex. The formulation of the present invention is a complex of polar and non-polar molecules prepared using the PNS technology, which increases the bio efficacy of nutraceutical ingredients. The formulation is prepared in powdered form using spray drying technology. The formulation is safe, effective in improving the gut health by maintaining gut microbiota in humans.

Description

A phytochemical formulation to improve gut health
DESCRIPTION OF THE INVENTION Technical field of the invention
[0001] The present invention relates to a phytochemical formulation for improvement of gut health. More particularly, the invention relates to a unique phytochemical formulation to maintain a healthy gut micro biota with controlling the inflammatory bowel disease symptoms.
Background of the invention
[0002] Health of gut or gastrointestinal tract (GI tract) is extremely important for overall well-being of the body. Since gut transports food from the mouth to the stomach, converts it into absorbable nutrients and stored energy, and shuttles waste back out of the body, it is also called as second brain of the body. The gut starts from the mouth and end at anus wherein this entire journey of food from mouth and anus determines how healthy a body is. Inflammation anywhere along the digestive tract disrupts this normal process and the main organs food goes through between mouth and anus include esophagus, stomach, small intestine, and large intestine.
[0003] Gut is full of trillions of bacteria that not only help to process food, but that also help body maintains homeostasis and overall well-being. This microflora may be unique to an individual and is primarily determined by the kind of food, a person consumes and how disciplined life he/she lives in terms of kind of food, sugar/fat levels, exercise, sleep time, medication, and stress levels. Further, research also indicates that babies delivered vaginally grow up to have more diverse microflora than those delivered via C-section, as they get exposed to different bacteria as they pass through the birth canal. Breastfeeding has also been shown to foster beneficial gut bacteria.
[0004] Gut microflora is key to many aspects of human health including immune system, metabolism and other neuro behavioral traits. The gut microbes are essential for the fermentation of non-digestible substrates like dietary fibers and endogenous intestinal mucus where this fermentation supports the growth of specialist microbes that produce short chain fatty acids (SCFAs) and gases, including acetate, propionate, and butyrate. Therefore, it is important to develop lifestyle habits that lead to good gut health.
[0005] One of the most complex implications of poor gut heath is inflammatory bowel disease (IBD), an umbrella term used to describe disorders that involve chronic inflammation of the digestive tract. Mainly there are 2 types of IBDs, Ulcerative colitis, involving inflammation and sores (ulcers) along the superficial lining of your large intestine (colon) and rectum and Chron's disease, characterized by inflammation of the lining of digestive tract, which often can involve the deeper layers of the digestive tract. IBD generally is considered to be an autoimmune disease, but research suggests that the chronic inflammation may not be due to the immune system attacking the body itself, but it is a result of the immune system attacking a harmless virus, bacteria, or food in the gut, causing inflammation that leads to bowel injury.
[0006] Inflammatory bowel disease symptoms vary, depending on the severity of inflammation and where it occurs. Symptoms may range from mild to severe. General signs and symptoms that are common to both Crohn's disease and ulcerative colitis include, diarrhea, fatigue, abdominal pain, stomach cramps, blood in your stool, reduced appetite, weight loss and anemia due to blood loss etc.
[0007] Anti-inflammatory drugs are often the first step in the treatment of inflammatory bowel disease as they decrease inflammation of the digestive tract. The medication generally includes immune suppressants, antidiarrheal drugs and laxatives that affect gut microflora and ecosystem adversely and have several side effects. [0008] The control of inflammatory bowel disease directly requires improvement and maintenance of gut health. Various types of medicines are available in the market today that claim to improve gut health. However, they do more harm to the body. There is a need to have a formulation that can naturally build and maintain gut health and reduce chances of developing inflammatory bowel disease.
Summary of the invention
[0009] In order to overcome the drawbacks of the existing prior art, the present invention discloses a formulation for maintaining gut health in humans.
[0010] The present invention discloses a phytochemical formulation comprising dietary fibers and standardized curcuminoids from Curcuma longa and Ferula asafoeitida extract. The standardized curcuminoids from Curcuma longa and Ferula asafoeitida extract are encapsulated in dietary fibers of turmeric forming a uniform matrix. The phytochemical formulation comprises dietary fibers obtained from Curcuma longa at a concentration of 90% -95%, standardized curcuminoids obtained from Curcuma longa at a concentration of 2% to 5% and Ferula asafoeitida extract at a concentration of 1% to 3%.
[0011] The formulation of the present invention is a complex of polar and non-polar molecules prepared using the PNS technology. Further, the complex prepared by the PNS technology improves the functional properties of the formulation, stability of the biomolecules, enhance the bio efficacy and controls release of the specific molecule of interest at the targeted tissues.
[0012] The formulation is prepared in powered form using the spray drying technology to enhance the efficacy of the formulation due to high surface area. Curcuminoids and Ferula asafoeitida extract are encapsulated on the dietary fibers of turmeric to form a firm and uniform complex and the encapsulation is confirmed by various analysis.
[0013] The safety and efficacy of the formulation of the present invention is analyzed for management of gut health and intestinal microflora in humans. The results indicated that the phytochemical formulation showed 27.16% increase in fecal bifidobacteria count and 23.97% increase in fecal lactobacillithus confirming the efficacy in improvement of gastrointestinal and gut health in humans without inducing any adverse effects in humans.
[0014] The formulation is natural, safe, and effective in improving the gut health and in maintaining gut microbiota in humans.
Brief Description of the drawings
[0015] FIG 1 tabulates the composition of the phytochemical formulation according to an embodiment of the invention.
[0016] FIG 2 illustrates the results of UPLC and GC-MS analysis of dietary fibers and the formulation of the present invention.
[0017] FIG 3 illustrates the results of the (FT-IR) spectra of dietary fibers and the formulation.
Detailed description of the invention
[0018] In order to more clearly and concisely describe and point out the subject matter of the claimed invention, the following definitions are provided for specific terms, which are used in the following written description.
[0019] The term “Gut” refers to gastrointestinal tract, which starts from the mouth to the anus which includes all the organs of the digestive system in humans and other animals.
[0020] The term “Gut microflora' refers to gut microbiome or the microorganisms living in the intestine,
[0021] The term “ Inflammatory Bowel Disease (IBD)” refers disorders that involve chronic inflammation of your digestive tract.
[0022] The term “PNS Technology ' refers to Polar-Nonpolar Sandwich (PNS) Technology, used to increase the bio efficacy of nutraceutieal ingredients. [0023] The term "Phytochemical" refers to the chemicals produced by plants through primary or secondary metabolism .
[0024] The present invention relates to a phytochemical formulation to improve the gut health. The formulation comprises the natural ingredients in processed form for maintaining a healthy gut microbiota by controlling the Inflammatory Bowel Disease (IBD) symptoms.
[0025] The formulation of the present invention comprises dietary fibers from Curcuma longa, standardized curcuminoids from Curcuma longa and non-volatile Ferula asafoeitida extract formed as a uniform matrix.
[0026] Curcuma longa, commonly termed as turmeric has been traditionally used in various medicines systems across the globe to manage many physical ailments. Similarly, Asafoetida is the dried latex i.e., gum oleoresin exuded from the rhizome or tap root of several species of Ferula perennial herbs, part of Umbelliferae family.
[0027] The phytochemical formulation of the present invention has been developed comprising dietary fiber, curcuminoids from Curcuma Longa rhizomes and non-volatile components of Ferula Asafoeitida using Polar-Nonpolar Sandwiching (PNS) Technology. PNS Technology is used to increase the bio-efficacy of nutraceutical ingredients.
[0028] FIG 1 tabulates the composition of the phytochemical formulation according to an embodiment of the invention. The formulation of the present invention comprises dietary fibers and curcuminoids from Curcuma longa and Ferula asafoeitida extract. The phytochemical formulation comprises dietary fibers obtained from Curcuma longa at a concentration of 90%-95%, standardized curcuminoids obtained from Curcuma longa at a concentration of 2% to 5% and Ferula asafoeitida extract at a concentration of 1% to 3%.
[0029] The presence of dietary fibers from Curcuma longa acts as a polar group and Ferula asafoeitida extract acts as a non-polar group and curcuminoids isolated from Curcuma longa is sandwiched between these polar and nonpolar matrices. [0030] The formulation forms a polar-non-polar sandwich complex, in which the active ingredients namely polar i.e., water soluble and non-polar i.e., oil soluble components penetrate the cell membrane and reach the blood plasma level. As a result, the efficacy and bioavailability of the formulation is increased.
[0031] The phytochemical formulation is prepared in which the bioactive ingredients curcuminoids and Ferula asafoeitida extract are encapsulated on to the turmeric fiber matrix. The turmeric fiber acts as a suitable carrier for encapsulating the bioactive ingredients to improve the efficacy.
[0032] The dietary fibers in the formulation influences in the gastrointestinal physiological functions and gut health of the host because of their physiochemical properties and capabilities of fermentation in the gut. The dietary fibers are complex carbohydrates containing of both soluble dietary fibers and insoluble dietary fibers. The soluble dietary fibers are fermented by assuring species of gut bacteria, prominent to physiologically active derivatives whereas the insoluble dietary fibers have significant bulking properties. The dietary fibers are degraded to produce short-chain fatty acids (SCFAs) by intestinal bacteria, which expand gastrointestinal health by stimulating the expression of porcine host defense peptides and altering the gut microbiota. The dietary fibers acts as prebiotic by specifically enhancing beneficial gut bacteria and thus improving human healthiness by its physical influence in the gut and improves the gut function.
[0033] The dietary fibers from Curcuma longa are a modified cell wall component of turmeric and is considered as a suitable carrier to encapsulate bioactive components such as curcuminoids and Ferula asafoeitida extract. In the formulation of the present invention, the curcuminoids and Ferula asafoeitida extract are encapsulated in the dietary fibers of Curcuma longa.
[0034] The formulation of the present invention is prepared using the PNS technology in which polar and non-polar molecules are formed as a complex. Further, the complex prepared by the PNS technology improves the functional properties of the formulation, stability of the biomolecules, enhance the bio efficacy and controls release of the specific molecule of interest at the targeted tissues.
[0035] The formulation is prepared in encapsulated form and is in powder form, which is prepared by spray drying. The powdered form of the encapsulated formulation increases the surface area thus improving the activity of the biomolecules used in the formulation.
[0036] The encapsulation of curcuminoids and Ferula asafoeitida extract on dietary fibers is confirmed by analysis of the formulation using Ultra Performance Liquid Chromatography (UPLC).
[0037] The mobile phase consists of 40% tetrahydrofuran and 60% water with 1% citric acid. The detection is carried out in an isocratic flow at a wavelength of 420 nm using a photodiode array (PDA) detector. The elution is carried out by isocratic method with 1 mL/min flow rate. The volatile oil is hydro-distilled from GHP for 6 h using Clevenger apparatus and dried over anhydrous sodium sulfate and stored in a refrigerator (8 ± 2 °C). The volatile oil is subjected to gas chromatography-mass spectrometry (GC-MS) analysis using Brucker 436-GC, couple with SCION TQMS by Rtx-624 fused silica column with 60 m column length and 0.25 mm internal diameter. The column temperature is maintained initially at 50 °C and gradually increased to a rate of 10 °C per minute till to attain 230 °C. Helium gas is used as a carrier gas at 1 mL/min of flow rate with constant pressure as 228 kPa.
[0038] FIG 2 illustrates the results of UPLC and GC-MS analysis of dietary fibers and the formulation of the present invention. The results indicated that presence of curcumin as depicted in FIG 2a. The GC-MS analysis of volatile oil of the formulation showed the presence of 2-mercapto-3,4-dimethyl-2,3-dihydrothiophene, n-propyl sec-butyl disulfide, 1 ,2-dithiolane, disulfide bis(l-methylpropyl), 1,3-dithiane, 2,2-bis(methylthio) propane and 1-(1 -propen- l-yl)-2-(2-thiophen-3-yl) disulfide as depicted in FIG 2b. The presence of these compounds confirms the encapsulation of curcuminoids and Ferula asafoeitida extract on dietary fibers. [0039] Fourier transform infrared (FT-IR) spectra of dietary fibers and the formulation are recorded by JASCO FT/IR-460 plus instrument in the range of 400-4000 cm-1 with 32 scans per sample using the grounded and blended samples with KBr in a ratio of sample/KBr at 1:4. The surface morphology of the dietary fibers, before and after encapsulation of bioactive compounds is determined using scanning electron microscopy (SEM). Elemental analysis is carried out by using Energy-dispersive X-ray spectroscopy (EDS) unit attached with SEM. The Samples are placed in aluminum stubs using doublesided carbon tape and sputter coated with a fine layer of gold using a sputter gold coater. All samples are examined using an accelerating voltage of 30 kV.
[0040] FIG 3 illustrates the results of the (FT-IR) spectra of dietary fibers and the formulation. The FT-IR spectra of dietary fibers and the formulation are elucidated in FIG. 3a and 3b respectively. In both the spectra, in the region of 3010-3653 cm-1, the broadened absorption band distinctive to the -OH stretching is observed and attributed to O-H stretching of hydrogen bound to the hydroxyl groups originating mainly from cellulose and hemicelluloses. The bands at 2854 and 2923 cm-1 are due to C-H stretching vibrations, which represented the presence of the typical structure of polysaccharide compounds. The prominent band of C-O-C pyranose ring skeletal vibration stretching around 1020 cm-1 observed in both spectra indicate the presence of xylans and is associated with hemi-celluloses, which confirmed that xyloglucans are strongly bound to dietary fibers and the intense band at this wavenumber proves high cellulose content in the formulation. The peak at 1633 cm-1 corresponded to bending or stretching aromatic hydrocarbons of lignin, which is one more main component of dietary nanofibers. In addition, the absorption band at 1155 cm-1 is contributed to the stretching of C-0 groups of C-O-C aliphatic esters. In the spectrum of the formulation the band at 1428 cm-1 indicates the olefin bending vibration of the C=C group bound to the benzene ring which is present in curcumin as depicted in the FIG 3b. The spectrum exhibited weak to medium intensity bands in the region 626 to 730 cm-1 due to the asymmetric and symmetric C-S stretching vibration due to the presence of more number of sulfur containing compounds which are present in Ferula asafoeitida extract. [0041] The characterization of the formulation confirms the encapsulation of curcuminoids and Ferula asafoeitida extract on dietary fibers of Curcuma longa.
[0042] The formulation of the present invention in analyzed for the management of gut health and intestinal microflora in human.
[0043] The following examples are offered to illustrate various aspects of the invention. However, the examples are not intended to limit or define the scope of the invention in any manner.
Example 1: The effect of the formulation in the management of gut health in human.
[0044] The safety and efficacy of the formulation of the present invention is analyzed for management of gut health and intestinal microflora in humans. A randomized, double- blind, placebo-controlled study is conducted in 30 humans out of which 20 are males and 10 are females, with ages ranging from 22 to 55 years after informed consent and evaluation of inclusion criteria. The effect of the formulation is analyzed on bifidobacteria and lactobacilli that are the indicators for gut health. The results indicated that the phytochemical formulation of the present invention showed 27.16% increase in fecal bifidobacteria count from screening stage to end of study, whereas the placebo group showed slight increase as 7.14%, Furthermore, the inter group analysis also showed a statistically significant p value (0.00026) based on the paired t-test. The formulation of the present invention also showed a significant result for fecal lactobacilli, which showed 23.97% increase in fecal lactobacilli count from the screening to end of study, whereas placebo group showed slight increase as 7.02%. In addition, the inter group analysis also showed a statistically significant p value (0.00067) based on the paired t-test. These results revealed that the phytochemical formulation is effective for improvement of gastrointestinal and gut health in humans.
[0045] Further, the formulation of the present invention did not show any significant change in lipid profile such as total cholesterol, triglycerides, HDL-C, LDL-C and VLDL, however, which has a tendency to decrease the levels of total cholesterol as3.90%, HDL-C as -18.37% and VLDL as -1.62%, due to the presence of dietary fibers in the formulation. However, the placebo group showed increase in total cholesterol as 0.64%, in triglycerides as 43.21% and in VLDL as 43.17%, which are also demonstrated the beneficial effect of the formulation over lipid profile, which is helpful in gastrointestinal and gut related problems and disorders.
[0046] The formulation of the present invention also exhibited significant reduction in Gastrointestinal Symptom Rating Scale (GSRS) with mean change reduction recorded as -28.57% between the study period, whereas the placebo showed increase in mean changes as 27.27%. There was statistically significant p value observed between the formulation and placebo study group based upon the paired t-test, which indicates an improvement in symptoms of gut health due to the administration of the formulation of the present invention. The changes in stool frequency assessed by BSS, the analysis of changes in BSS indicated positive stool changes in treatment group without inducing any adverse effects. This indicates the efficacy of the formulation in improvement of gut health in humans.
[0047] The formulation of the present invention includes spices, herbs and plant derived phytochemicals having the scientific superiority of low toxicity and superior bio efficacy. As the formulation is derived from the natural ingredients, it is safe for consumption without inducing any adverse effects on gut microflora.
[0048] The formulation of the present invention prepared by spray drying with improved characteristics such as bulk density is safe and effective in improvement of gut health micro biota by controlling the inflammatory bowel disease symptoms.

Claims

Claims: We Claim,
1. A phytochemical formulation to improve the gut health, the formulation comprises: a. dietary fiber rich fraction isolated from Curcuma longa at a concentration of 90%-95%; b. curcuminoids rich fraction isolated from rhizome of Curcuma longa at a concentration of 2% to 5%; and c. Ferula asafoeitida extract at a concentration of 1% to 3%
Wherein curcuminoids rich fraction and Ferula asafoeitida extract are encapsulated onto dietary fiber to form a uniform polar-non-polar complex.
2. The formulation as claimed in claim 1, wherein curcuminoids rich fraction and Ferula asafoeitida extract forms a complex with dietary fiber rich fraction from Curcuma longa
3. The formulation as claimed in claim 1, wherein the polar-non-polar complex penetrate the cell membrane and reach the blood plasma level to improve the bioavailability.
4. The formulation as claimed in claim 1, wherein the formulation is useful in powder form of administration.
5. The formulation as claimed in claim 1, wherein the formulation improved gut microbiota by increasing 27.16% of fecal bifidobacteria count in human.
6. The formulation as claimed in claim 1, wherein the formulation improved gut microbiota by increasing 23.97% of fecal lactobacilli count in human.
7. The formulation as claimed in claim 1, wherein the formulation reduced inflammatory bowel disease symptoms in human.
PCT/IB2022/056044 2021-06-30 2022-06-29 A phytochemical formulation to improve gut health WO2023275776A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202141029293 2021-06-30
IN202141029293 2021-06-30

Publications (1)

Publication Number Publication Date
WO2023275776A1 true WO2023275776A1 (en) 2023-01-05

Family

ID=84691571

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2022/056044 WO2023275776A1 (en) 2021-06-30 2022-06-29 A phytochemical formulation to improve gut health

Country Status (1)

Country Link
WO (1) WO2023275776A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100396294C (en) * 2005-08-15 2008-06-25 王彦丁 Application of resina ferulae in preparation of medicament for treating irritable bowel syndrome(IBS)
WO2018033893A1 (en) * 2016-08-19 2018-02-22 Aurea Biolabs Private Limited A method for extraction of dietary fibers from spices
IN201641034767A (en) * 2016-10-12 2018-04-13 Aurea Biolabs Private Limited

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100396294C (en) * 2005-08-15 2008-06-25 王彦丁 Application of resina ferulae in preparation of medicament for treating irritable bowel syndrome(IBS)
WO2018033893A1 (en) * 2016-08-19 2018-02-22 Aurea Biolabs Private Limited A method for extraction of dietary fibers from spices
IN201641034767A (en) * 2016-10-12 2018-04-13 Aurea Biolabs Private Limited

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "IS THERE AN IDEAL DIET FOR IRRITABLE BOWEL SYNDROME? WHY A MULTIDIMENSIONAL APPROACH MAY BE BEST", 16 January 2019 (2019-01-16), pages 1 - 12, XP093022424, Retrieved from the Internet <URL:https://altmedrev.com/blog/is-there-an-ideal-diet-for-irritable-bowel-syndrome-why-a-multidimensional-approach-may-be-best/> [retrieved on 20230209] *
DATABASE TKDL 3 March 2010 (2010-03-03), ANONYMOUS : "Dawa Baraye Kabid Wa Tihaal", XP093022439, retrieved from TKDL Database accession no. MH5/144 *

Similar Documents

Publication Publication Date Title
Goh et al. Genistein: A review on its anti-inflammatory properties
Dingeo et al. Phytochemicals as modifiers of gut microbial communities
Xiao et al. Rice bran phenolic extract protects against alcoholic liver injury in mice by alleviating intestinal microbiota dysbiosis, barrier dysfunction, and liver inflammation mediated by the endotoxin–TLR4–NF-κB pathway
Zhang et al. Sargassum fusiforme fucoidan alleviates high-fat diet-induced obesity and insulin resistance associated with the improvement of hepatic oxidative stress and gut microbiota profile
Hassan et al. Obesity and clinical riskiness relationship: therapeutic management by dietary antioxidant supplementation—a review
Jiang et al. Effect of Durio zibethinus rind polysaccharide on functional constipation and intestinal microbiota in rats
Wong et al. Deleterious effect of p-cresol on human colonic epithelial cells prevented by proanthocyanidin-containing polyphenol extracts from fruits and proanthocyanidin bacterial metabolites
Gopi et al. Preparation, characterization and anti-colitis activity of curcumin-asafoetida complex encapsulated in turmeric nanofiber
Jaswir et al. Isolation of fucoxanthin and fatty acids analysis of Padina australis and cytotoxic effect of fucoxanthin on human lung cancer (H1299) cell lines
Han et al. Cactus (Opuntia humifusa) water extract ameliorates loperamide-induced constipation in rats
Pan et al. Regulatory effect of Grifola frondosa extract rich in polysaccharides and organic acids on glycolipid metabolism and gut microbiota in rats
TWI801925B (en) Aloe based compositions comprising polysaccharides and polyphenols for regulation of homeostasis of immunity
Jayachandran et al. A critical review on diet-induced microbiota changes and cardiovascular diseases
Reyes et al. Selected phyto and marine bioactive compounds: Alternatives for the treatment of type 2 diabetes
Li et al. Anti-obesity natural products and gut microbiota
Wu et al. Protective effects of six different pectic polysaccharides on DSS-induced IBD in mice
Guo et al. Research on the structural characteristics of a novel Chinese Iron Yam polysaccharide and its gastroprotection mechanism against ethanol-induced gastric mucosal lesion in a BALB/c mouse model
Miaffo et al. Antidiabetic and antioxidant potentials of Vitellaria paradoxa barks in alloxan-induced diabetic rats
JP2019534331A (en) Compositions that promote intestinal health
Xue et al. Polysaccharides from hemp seed protect against cyclophosphamide-induced intestinal oxidative damage via Nrf2-Keap1 signaling pathway in mice
Nosáľová et al. Suppressive effect of pectic polysaccharides from Cucurbita pepo L. var. Styriaca on citric acid-induced cough reflex in guinea pigs
Li et al. 6, 7-Dihydroxy-2, 4-dimethoxyphenanthrene from Chinese yam peels alleviates DSS-induced intestinal mucosal injury in mice via modulation of the NF-κB/COX-2 signaling pathway
Salih Applications of gum arabic in medical and health benefits
Liu et al. Superfruits in China: Bioactive phytochemicals and their potential health benefits–A Review
Vargas-Mendoza et al. Phytochemicals in skeletal muscle health: effects of curcumin (from Curcuma longa Linn) and sulforaphane (from Brassicaceae) on muscle function, recovery and therapy of muscle atrophy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22832311

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE